Clinical Trials
28 trialsStudy of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
UPLIFT
Massachusetts General Hospital
FLEX
Amphia Hospital
ICEMELT
Western Sydney Local Health District
UNITO-001
University of Turin, Italy
Studying the Clinical Trial Experiences of Patients With Mesothelioma
Power Life Sciences Inc.
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Sohag University
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Hospices Civils de Lyon
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
University of Maryland, Baltimore
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
MARS2
Royal Brompton & Harefield NHS Foundation Trust
HIPEC/IPHC
Bay Area Gynecology Oncology
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
Ain Shams University
MesoCancerVa
Erasmus Medical Center
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Brigham and Women's Hospital
SKOPOS
Wales Cancer Trials Unit
Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos
British Columbia Cancer Agency
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Columbia University
AGILI
Institute of Oncology Ljubljana
SMS
King's College London
IPHC
Wuhan University
TL139
Taxolog Inc.
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma